Oramed Pharmaceuticals

Oramed Pharmaceuticals FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Oramed Pharmaceuticals (ORMP) as of Nov 7, 2026 is -17.30 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 44.23 % — a change of -139.11% (lower).

FCF Conversion

-17.30 %

YoY

-139.11%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Oramed Pharmaceuticals is 2025 -17.30 % . FCF Conversion Rate (FCF/EBITDA) of Oramed Pharmaceuticals was 2024 44.23 % . It decreases by -139.11% lower compared to the previous year.

The Oramed Pharmaceuticals FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
115.20 USD
Jan 1, 2019
90.25 USD
Jan 1, 2020
108.78 USD
Jan 1, 2021
96.93 USD
Jan 1, 2022
77.31 USD
Jan 1, 2023
-190.93 USD
Jan 1, 2024
44.23 USD
Jan 1, 2025
-17.30 USD
The Oramed Pharmaceuticals FCF Conversion history
YEARFCF ConversionYoY
-17.30 %-139.11%
44.23 %-123.16%
-190.93 %-346.96%
77.31 %-20.24%
96.93 %-10.89%
108.78 %+20.54%
90.25 %-21.66%
115.20 %+106.81%
55.71 %-231.46%
-42.38 %-161.95%
68.40 %-4.55%
71.66 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oramed Pharmaceuticals Stock analysis

What does Oramed Pharmaceuticals do? Oramed Pharmaceuticals Inc is an innovative biotech company headquartered in Jerusalem, Israel. The company was founded in 2006 by Nadav Kidron and specializes in the development of oral forms of protein-based therapeutics. The idea behind Oramed Pharmaceuticals was to revolutionize the way proteins are administered. Typically, protein-based drugs like insulin need to be administered in injectable form, which can be unpleasant and painful for many patients. Oramed Pharmaceuticals set out to find a solution to this problem. The company has developed a technology called ORMD-0801, which allows for the oral administration of insulin. The active ingredient is protected by a special capsule that monitors the pH level in the stomach. Once the capsule reaches the small intestine, the active ingredient is released and can be absorbed by the body. Oramed Pharmaceuticals aims to improve the treatment of diabetes. With the oral form of insulin, patients can take their medication much easier and more conveniently. This can help improve treatment and increase patients' quality of life. In addition to the development of ORMD-0801, Oramed Pharmaceuticals is also working on developing oral forms of other protein-based therapeutics. The company has filed a variety of patents for technologies and therapies and actively collaborates with other companies and research institutions. Oramed Pharmaceuticals has two main divisions: the development department and the commercialization department. The development department is responsible for the research and development of new therapies, while the commercialization department is responsible for sales and marketing of the products. Oramed Pharmaceuticals' business model is focused on developing innovative therapies and bringing them to market. The company works closely with other companies and research institutions to advance the development of new therapies. Oramed Pharmaceuticals is currently working on several projects to develop additional orally administered protein-based therapeutics. In addition to insulin, the company is also working on proteins that can be used in the treatment of other diseases such as osteoporosis and Parkinson's. The products of Oramed Pharmaceuticals are of great importance to both patients and the medical community. The oral forms of protein-based therapeutics can help make the treatment of diabetes and other diseases much easier and more convenient. This can help increase patient satisfaction and improve compliance. In recent years, Oramed Pharmaceuticals has received several awards and accolades for its innovative products. The company continues to work on developing new therapies and changing the way medication is administered. Oramed Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oramed Pharmaceuticals stock

FCF Conversion Rate (FCF/EBITDA) of Oramed Pharmaceuticals is -17.30 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Oramed Pharmaceuticals changed from 44.23 % to -17.30 %, representing a -139.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Oramed Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Oramed Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Oramed Pharmaceuticals

All Key Metrics — Oramed Pharmaceuticals